[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

HUP0105090A2 - Kóros elhízás elleni fehérjék expressziója és exportja Fc fúziós fehérje formájában - Google Patents

Kóros elhízás elleni fehérjék expressziója és exportja Fc fúziós fehérje formájában

Info

Publication number
HUP0105090A2
HUP0105090A2 HU0105090A HUP0105090A HUP0105090A2 HU P0105090 A2 HUP0105090 A2 HU P0105090A2 HU 0105090 A HU0105090 A HU 0105090A HU P0105090 A HUP0105090 A HU P0105090A HU P0105090 A2 HUP0105090 A2 HU P0105090A2
Authority
HU
Hungary
Prior art keywords
obesity
proteins
fusion proteins
export
expression
Prior art date
Application number
HU0105090A
Other languages
English (en)
Inventor
Stephen D. Gillies
Kin-Ming Lo
Jinyang Zhang
Original Assignee
Lexigen Pharmaceuticals Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lexigen Pharmaceuticals Corporation filed Critical Lexigen Pharmaceuticals Corporation
Publication of HUP0105090A2 publication Critical patent/HUP0105090A2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Endocrinology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

A tal lm ny t rgy t ltal noss gban kóros elhíz s elleni fehérjéttartalmazó fúziós fehérjék elő llít s ra szolg ló elj r sok, tov bbalkalmaz sukhoz szükséges készítmények képezik. K"zelebbről, a tal lmny t rgy t fúziós fehérjék elő llít s ra szolg ló elj r sok valamintazok alkalmaz s hoz szükséges készítmények képezik, amelyekben afúziós fehérjék immunglobulin Fc régiót és leptin kóros elhíz s ellenifehérjét tartalmaznak. A tal lm ny szerinti megold s alkalmas kóroselhíz s megelőzésére és kezelésére. Ó
HU0105090A 1999-01-07 2000-01-07 Kóros elhízás elleni fehérjék expressziója és exportja Fc fúziós fehérje formájában HUP0105090A2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11507999P 1999-01-07 1999-01-07
PCT/US2000/000352 WO2000040615A2 (en) 1999-01-07 2000-01-07 EXPRESSION AND EXPORT OF ANTI-OBESITY PROTEINS AS Fc FUSION PROTEINS

Publications (1)

Publication Number Publication Date
HUP0105090A2 true HUP0105090A2 (hu) 2002-04-29

Family

ID=22359200

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0105090A HUP0105090A2 (hu) 1999-01-07 2000-01-07 Kóros elhízás elleni fehérjék expressziója és exportja Fc fúziós fehérje formájában

Country Status (16)

Country Link
US (1) US20040053366A1 (hu)
EP (1) EP1141013A2 (hu)
JP (1) JP2002534962A (hu)
KR (1) KR20020007287A (hu)
CN (1) CN1341121A (hu)
AU (1) AU778939B2 (hu)
BR (1) BR0007414A (hu)
CA (1) CA2356401A1 (hu)
CZ (1) CZ20012406A3 (hu)
HU (1) HUP0105090A2 (hu)
ID (1) ID30327A (hu)
MX (1) MXPA01006922A (hu)
NO (1) NO20013371L (hu)
SK (1) SK9432001A3 (hu)
WO (1) WO2000040615A2 (hu)
ZA (1) ZA200105352B (hu)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1037927B1 (en) 1997-12-08 2004-05-19 Lexigen Pharmaceuticals Corp. Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation
US20030105294A1 (en) * 1998-02-25 2003-06-05 Stephen Gillies Enhancing the circulating half life of antibody-based fusion proteins
CZ20003767A3 (cs) * 1998-04-15 2002-01-16 Lexigen Pharmaceuticals Corp. Kompozice pro indukci imunitní odpovědi vůči zvolenému typu buňek v organismu savce a její pouľití pro výrobu léčiva
SK782002A3 (en) * 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
ATE316982T1 (de) * 1999-08-09 2006-02-15 Lexigen Pharm Corp Mehrere zytokin-antikörper komplexen
US20050202538A1 (en) * 1999-11-12 2005-09-15 Merck Patent Gmbh Fc-erythropoietin fusion protein with improved pharmacokinetics
DE60122286T2 (de) * 2000-02-11 2007-08-02 Merck Patent Gmbh Steigerung der zirkulierenden halbwertzeit von auf antikörpern basierenden fusionsproteinen
EP1294401B1 (en) * 2000-06-29 2007-08-01 EMD Lexigen Research Center Corp. Enhancement of antibody-cytokine fusion protein mediated immune responses by combined treatment with immunocytokine uptake enhancing agents
ATE400030T1 (de) 2001-02-19 2008-07-15 Merck Patent Gmbh Methode zur identifizierung von t-zellepitopen und deren anwendung zur herstellung von molekülen mit reduzierter immunogenität
PL362324A1 (en) * 2001-02-19 2004-10-18 Merck Patent Gmbh Artificial fusion proteins with reduced immunogenicity
KR20090010127A (ko) * 2001-03-07 2009-01-28 메르크 파텐트 게엠베하 하이브리드 이소타입 항체 부분구조를 포함하는 단백질을 위한 발현 기술
WO2002079415A2 (en) * 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
BR0209177A (pt) * 2001-05-03 2004-10-05 Merck Patent Gmbh Anticorpo especìfico a tumor recombinante e uso do mesmo
EP2354791A1 (en) 2001-12-04 2011-08-10 Merck Patent GmbH Immunocytokines with modulated selectivity
BRPI0317376B8 (pt) * 2002-12-17 2021-05-25 Merck Patent Gmbh proteína de fusão de anticorpo-il2 designada como hu14.18-il2, usos da mesma, vetor e composição farmacêutica
US20050069521A1 (en) * 2003-08-28 2005-03-31 Emd Lexigen Research Center Corp. Enhancing the circulating half-life of interleukin-2 proteins
EP1697415A1 (en) 2003-11-12 2006-09-06 Biogen Idec MA Inc. NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO
CN1723220A (zh) 2003-11-13 2006-01-18 韩美药品工业株式会社 含有免疫球蛋白fc区作为载体的药物组合物
US8110665B2 (en) 2003-11-13 2012-02-07 Hanmi Holdings Co., Ltd. Pharmaceutical composition comprising an immunoglobulin FC region as a carrier
CN100467488C (zh) 2003-12-30 2009-03-11 默克专利有限公司 Il-7融合蛋白
WO2005063808A1 (en) * 2003-12-31 2005-07-14 Merck Patent Gmbh Fc-ERYTHROPOIETIN FUSION PROTEIN WITH IMPROVED PHARMACOKINETICS
JP2007517506A (ja) 2004-01-05 2007-07-05 イーエムディー・レキシゲン・リサーチ・センター・コーポレーション 標的化用化合物
WO2005070967A2 (en) * 2004-01-22 2005-08-04 Merck Patent Gmbh Anti-cancer antibodies with reduced complement fixation
US7670595B2 (en) * 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
CN101072793B (zh) * 2004-12-09 2012-06-20 默克专利有限公司 具有降低的免疫原性的il-7变体
EP2311881A3 (en) 2005-01-05 2011-07-27 Biogen Idec MA Inc. Cripto binding molecules
US7566456B2 (en) * 2005-06-23 2009-07-28 Haiming Chen Allergen vaccine proteins for the treatment and prevention of allergic diseases
EP1909823A2 (en) * 2005-07-29 2008-04-16 Amprotein Corporation Chimeric therapeutic agents
US8227408B2 (en) * 2005-09-07 2012-07-24 Neurotez, Inc. Leptin as an anti-amyloidogenic biologic and methods for delaying the onset and reducing Alzheimer's disease-like pathology
US20070104689A1 (en) * 2005-09-27 2007-05-10 Merck Patent Gmbh Compositions and methods for treating tumors presenting survivin antigens
EP1801121A1 (en) * 2005-12-23 2007-06-27 CONARIS research institute AG Soluble gp130 molecule variants useful as a medicament
ATE555125T1 (de) * 2005-12-30 2012-05-15 Merck Patent Gmbh Interleukin-12p40-varianten mit verbesserter stabilität
EA016429B1 (ru) 2005-12-30 2012-04-30 Мерк Патент Гмбх Антитела против cd19 с пониженной иммуногенностью
US7846434B2 (en) * 2006-10-24 2010-12-07 Trubion Pharmaceuticals, Inc. Materials and methods for improved immunoglycoproteins
US20080227669A1 (en) * 2007-03-12 2008-09-18 Halliburton Energy Services, Inc. Corrosion-inhibiting additives, treatment fluids, and associated methods
CN102099048A (zh) 2008-05-21 2011-06-15 纽若泰兹公司 用于治疗与神经原纤维缠结有关的进行性认知障碍的方法
KR20120024529A (ko) 2008-11-04 2012-03-14 니콜라오스 테자프시디스 신경섬유 매듭 및 아밀로이드 베타의 축적으로부터 기인하는 진행성 인지 기능 장애의 치료용 렙틴 조성물 및 치료 방법
AU2010238858A1 (en) 2009-04-22 2011-12-08 Merck Patent Gmbh Antibody fusion proteins with modified FcRn binding sites
AU2012240102C1 (en) 2011-04-08 2016-09-08 Amgen Inc. Method of treating or ameliorating metabolic disorders using growth differentiation factor 15 (GDF-15)
US11492383B2 (en) 2011-06-24 2022-11-08 Stephen D. Gillies Light chain immunoglobulin fusion proteins and methods of use thereof
EA201491413A1 (ru) 2012-01-26 2015-03-31 Эмджен Инк. Полипептиды фактора роста и дифференцировки 15 (gdf-15)
ES2602030T3 (es) 2012-08-02 2017-02-17 F. Hoffmann-La Roche Ag Método para producir RFc solubles como fusión de Fc con la región Fc de inmunoglobulina inerte y usos de los mismos
SG11201408530YA (en) * 2012-08-02 2015-03-30 Hoffmann La Roche Method for producing monomeric and multimeric molecules and uses thereof
PE20150648A1 (es) * 2012-09-07 2015-05-25 Sanofi Sa Proteinas de fusion para el tratamiento de un sindrome metabolico
EA037355B1 (ru) * 2013-07-31 2021-03-17 Эмджен Инк. Конструкции на основе фактора дифференцировки и роста 15 (gdf-15)
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
EP3433264A4 (en) 2016-03-21 2019-08-28 Children's Medical Center Corporation COMPOSITIONS AND METHODS FOR INHIBITING WNT SIGNALING
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
US20180009869A1 (en) * 2016-07-08 2018-01-11 AskGene Pharma, Inc. Fusion Protein Comprising Leptin and Methods for Producing and Using the Same
US11779604B2 (en) 2016-11-03 2023-10-10 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses and methods
SG11202009884YA (en) 2018-04-09 2020-11-27 Amgen Inc Growth differentiation factor 15 fusion proteins
US11197910B1 (en) * 2020-08-19 2021-12-14 Vitruviae LLC Fusion proteins for the diagnosis, prophylaxis and treatment of infectious diseases

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6309853B1 (en) * 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US5541087A (en) * 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
WO1996031526A1 (en) * 1995-04-06 1996-10-10 Amylin Pharmaceuticals, Inc. Anti-obesity agents
GB9511935D0 (en) * 1995-06-13 1995-08-09 Smithkline Beecham Plc Novel compound

Also Published As

Publication number Publication date
EP1141013A2 (en) 2001-10-10
US20040053366A1 (en) 2004-03-18
AU778939B2 (en) 2004-12-23
MXPA01006922A (es) 2002-04-24
WO2000040615A2 (en) 2000-07-13
CA2356401A1 (en) 2000-07-13
KR20020007287A (ko) 2002-01-26
BR0007414A (pt) 2001-10-16
CN1341121A (zh) 2002-03-20
AU2602500A (en) 2000-07-24
ID30327A (id) 2001-11-22
NO20013371L (no) 2001-09-04
CZ20012406A3 (cs) 2002-03-13
ZA200105352B (en) 2002-06-28
JP2002534962A (ja) 2002-10-22
NO20013371D0 (no) 2001-07-06
WO2000040615A3 (en) 2000-11-23
SK9432001A3 (en) 2003-02-04

Similar Documents

Publication Publication Date Title
HUP0105090A2 (hu) Kóros elhízás elleni fehérjék expressziója és exportja Fc fúziós fehérje formájában
HUP0104717A2 (hu) Készítmények és eljárások petefészekrák terápiájára és diagnózisára
EE200200510A (et) POL1212 aminohappejärjestust kodeeriv DNA, seda sisaldav ekspressioonivektor, sea modifitseeritud VIII- tegur, sellel põhinev ravimkompositsioon ningmeetod sea modifitseeritud VIII-teguri aminohappejärjestust omava valgu valmistamiseks
MXPA03006771A (es) Anticuerpos modificados y metodos de uso.
WO2002054081A3 (en) Proteins, genes and their use for diagnosis and treatment of kidney response
WO2001096587A3 (en) Methods for administering recombinant adeno-associated virus virions to humans previously exposed to adeno-associated virus
Hill et al. Carcinoembryonic antigen‐related cell adhesion molecule (CEACAM)‐binding recombinant polypeptide confers protection against infection by respiratory and urogenital pathogens
WO2003000851A3 (en) Method for rapid screening of bacterial transformants and novel simian adenovirus proteins
PT1090033E (pt) Particulas de proteinas de envelope do hcv: utilizacao para vacinacao
WO2002072636A3 (en) Crystals of whole antibodies and fragments thereof and methods for making and using them
WO2002021141A3 (en) Methods and compositions for diseases associated with amyloidosis
JP2002544238A5 (hu)
EP1127170A4 (en) HUMAN MONOCLONAL ANTIBODIES TO HUMAN PAN-HEPATITIS C VIRUS
HUP0400284A2 (hu) Rekombináns, tumorspecifikus ellenanyag és alkalmazása
ATE376559T1 (de) Methoden der verhinderung und behandlung der alzheimer'schen krankheit
ATE430200T1 (de) Impstoff gegen den für atemwegs- und reproduktionserkrankungen beim schwein verantwortlichen virus
BR9814276A (pt) Antìgenos de superfìcie
PT1042363E (pt) Novos imunogenes anti-hiv (toxóides), processos de preparação e de aplicação para a prevenção e para o tratamento do sida
NO20025153D0 (no) FremgangsmÕter og sammensetninger for Õ svekke formering av HIV-1
HUP0105490A2 (hu) Az IgE C-epszilon-3 vagy C-epszilon-4 doménjéből származtatott epitópok és mimotópok, antagonistáik és terápiás alkalmazásuk
NO320151B1 (no) Konjugat mellom en biospesifikk affinitetsmotpart og et peptid avledet fra et superantigen som er kovalent bundet til hverandre
UA42040C2 (uk) Поліпептид, спосіб діагностики інсулінозалежного цукрового діабету (iddm), що розвинувся або що розвивається (варіанти), набір для діагностики iddm (варіанти), препарат для запобігання або лікування iddm, фармацевтична композиція для профілактики або лікування iddm
HUP0303126A2 (hu) Vektorok molekuláknak CD11b-t expresszáló sejtekhez történő szállítására
CY1111431T1 (el) Μεταλλαγμενες πρωτεϊνες πλακουντιου αυξητικου παραγοντα τυπου 1, μεθοδος παρασκευης και εφαρμογες αυτων
HUP9901688A2 (hu) A diabétesz kezelésére szolgáló, humán hősokk protein 60-ból származó új peptidek, készítmények, eljárások és kitek